FDA regulatory momentum includes priority review and breakthrough therapy designation for a potential first-in-class CHB ...
In adults with chronic hepatitis B infection receiving viral suppression therapy, coupling an investigational small interfering RNA therapy with an immunomodulator led to substantial declines in blood ...
Please provide your email address to receive an email when new articles are posted on . The FDA granted marketing authorization for Cepheid’s Xpert HCV test and GeneXpert Xpress System, the first ...
Why does Hepatitis E become chronic in some patients, and why do medications not work? To find out, an international research team led by scientists from Bochum observed a patient with chronic ...
Please provide your email address to receive an email when new articles are posted on . Serum HBV RNA declines at 1 and 2 years were independently associated with risk for HCC. Patients with less ...
Both tobevibart (a monoclonal antibody) and elebsiran (a small interfering RNA) target hepatitis B virus surface antigen (HBsAg). Their efficacy and safety in the treatment of chronic hepatitis D ...
The FDA has accepted for Priority Review the New Drug Application for bepirovirsen for the treatment of adults with chronic hepatitis B.
Millions of people in the U.S. and around the world are living with hepatitis C virus (HCV). But over the past decade, direct-acting antivirals (DAA) have proven effective against HCV, curing more ...
A study of more than 4,500 US infants exposed to hepatitis C virus (HCV) in utero or at birth from 2014 to 2021 finds that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results